Table 2 Intraoperative characteristics and outcomes between Non-AKI group and AKI group

 Nadir MAP (mmHg), mean ± SD

71.52 ± 8.19

66.92 ± 12.33

 Hypotension, n(%)

145 (19.2%)

19 (47.5%)

 Norepinephrine use, n(%)

72 (9.5%)

9 (22.5%)

 Dopamine use, n(%)

16 (2.1%)

1 (2.5%)

 Milrinone use, n(%)

91 (12.0%)

6 (15.0%)

 Received red blood cell, n(%)

76 (10.1%)

11 (27.5%)

 Received plasma, n(%)

45 (6.0%)

9 (22.5%)

 Crystalloid (ml), Median [25th to 75th P]

1500 [1000–1500]

1500 [1000–2000]

 Hydroxyethyl starch (ml), Median [25th to 75th P]

500 [500–500]

500 [500–1000]]

 Blood loss (ml), Median [25th to 75th P]

200 [100–300]

300 [100–775]

 Urine volume (ml), Median [25th to 75th P]

400 [200–500]

500 [263–700]

 Clamping of portal vein times (n), Median [25th to 75th P]

1 [1–2]

2 [1–2]

 Clamping of portal vein duration (min), Median [25th to 75th P]

20 [15–30]

25 [17–30]

 Surgery duration (hours), Median [25th to 75th P]

3.0 [2.5–4.0]

4.0 [3.1–4.5]

 Peak AST (IU/L), Median [25th to 75th P]

172.9 [101.9–313.0]

303.7 [151.5–721.0]

 Peak ALT (IU/L), Median [25th to 75th P]

182 [106–337]

269 [150–715]

 Peak sCr (μmol/L), Median [25th to 75th P]

64.0 [53.0–76.1]

91.5 [74.4–138.5]

 Minimum eGFR (ml/min/1.73m²), Median [25th to 75th P]

81.2 [68.1–100.6]

53.1 [38.4–69.7]

 Peak BUN (μmol/L), Median [25th to 75th P]

5.7 [4.8–6.8]

7.3 [5.5–10.0]

ICU admission, n(%)

46 (6.1%)

7 (17.5%)

Hospital length of stay (days), Median [25th to 75th P]

12 [10–14]

14 [10–20]

Re-operation, n(%)

4 (0.5%)

1 (2.5%)

Mortality, n(%)

2 (0.3%)

1 (2.5%)